Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
Resident Doctor at Clinical Pathology Department
Asmaa Hassan mohamed Abdel Mawjoud
38 participants
Mar 20, 2027
OBSERVATIONAL
Conditions
Summary
CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.
Eligibility
Inclusion Criteria2
- Patients with hematologic malignancies.
- Newly diagnosed
Exclusion Criteria1
- Patients with hematologic disorders other than hematologic malignancies.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
detection of CD56 by flow cytometry
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04546945